Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another installment of The Health Kick Podcast.
In this episode Tim interviews Michael Harsh, non-executive director at Imagion Biosystems (ASX:IBX).
Imagion Biosystems is developing a diagnostic imaging tool called Magsense, which is based on injecting nanoparticles with magnetic fields to detect tumors such as breast cancers.
Listen to the podcast.
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited